ZILA Zila (MM)

Zila, Inc. (NASDAQ:ZILA) today announced that it has selected Intertrade Dental A.E.S.A. to be the exclusive distributor of ViziLite� Plus with TBlue�, Zila�s proprietary oral cancer screening product, in Greece and Cyprus. Intertrade has placed orders for ViziLite Plus and plans to immediately begin training its sales representatives and preparing the market for the product launch. Terms of the agreement were not disclosed. �ViziLite Plus will provide dental professionals in Greece and Cyprus with an effective screening tool in the fight against oral cancer," said David Bethune chairman and chief executive officer of Zila. �We have experience working with Intertrade and we are confident they will be a first rate marketing partner. Greece and Cyprus represent good markets in our continuing efforts to expand our geographical footprint for ViziLite Plus.� ViziLite� Plus with TBlue�, the company's flagship product for the early detection of oral abnormalities that could lead to cancer, is the first and only adjunctive medical device cleared by the FDA for use in a population at increased risk for oral cancer. Peter Chrissopolous of Intertrade Dental commented, �ViziLite Plus is an exciting new product for our business and we are pleased to bring this unique and effective oral cancer screening system to dental professionals throughout Greece and Cyprus.� The combined population of Greece and Cyprus is approximately 11.5 million. About Oral Cancer and ViziLite Plus Oral cancer is the sixth leading cause of cancer worldwide, and while tobacco and alcohol use are known risk factors, one quarter of all oral cancer cases occur in men and women with no risk behaviors. According to American Cancer Society data, nearly as many women will be diagnosed with oral cancer as with cervical cancer this year. The key to reducing the impact of this disease is early detection. ViziLite Plus, an oral screening technology that utilizes a chemiluminescent light source (ViziLite) and a patented pharmaceutical-grade vital tissue dye (TBlue), helps dentists and dental technicians identify and evaluate abnormalities in the mouth that could potentially harbor pathologic changes. The ViziLite Plus exam takes only minutes and is totally painless and non-invasive. Zila began direct marketing ViziLite Plus in the U.S. in February 2007, Canada in November 2007, and the UK in May 2008. Oral Cancer Risk factors: -- age - all adults -- gender - more men than women develop oral cancer -- smoking - particularly if combined with heavy alcohol consumption -- chewing tobacco or using snuff -- heavy alcohol consumption - particularly if combined with smoking -- excessive sun exposure to the lips A recent report in the New England Journal of Medicine suggests that exposure to the sexually transmitted human papillomavirus number 16 (HPV16), causes oropharyngeal cancer (a type of oral cancer), and may help explain the increasing incidence of the disease in younger people. About Intertrade Dental Intertrade Dental AE is the first company in Greece with a full range of mechanical and chemical means of oral hygiene. Intertrade Dental was founded in 1989 and is based in Kryoneri Attiki, an industrial park just outside Athens, Greece. The company sells products to dental offices and clinics and through direct sales to pharmacies. The company participates in scientific events, conferences and dental congresses. About Zila, Inc. Zila, Inc. is a fully integrated oral diagnostic company dedicated to the prevention, detection and treatment of oral cancer and periodontal disease. ViziLite� Plus with TBlue�, the company's flagship product for the early detection of oral abnormalities that could lead to cancer, is the first and only adjunctive medical device cleared by the FDA for use in a population at increased risk for oral cancer. In addition, Zila designs, manufactures and markets a suite of proprietary products sold exclusively and directly to dental professionals for periodontal disease, including the Rotadent� Professional Powered Brush, the Pro-Select Platinum� ultrasonic scaler and a portfolio of oral pharmaceutical products for both in-office and home-care use. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely affect revenue, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31, 2007 and Form 10-Q for the quarter ended April 30, 2008. For more information about the company and its products, please visit www.zila.com.